Activity Overview
COVID-19 remains a significant challenge for health care systems, contributing to lengthy hospitalizations, long-term health complications, and costly economic burdens. High-risk populations remain vulnerable to severe disease outcomes, with prevention remaining a key component of management. This CME-certified Medical Crossfire® podcast is the second in a 3-part series titled Primary Care Playbook Podcast: Advancing COVID-19 Prophylaxis in Community Practice. In this activity, 3 expert faculty in Family Medicine, Geriatric Medicine, and Infectious Disease exchange unique perspectives and discuss practical approaches to choosing appropriate COVID-19 prevention strategies in clinical practice, including pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), individualized patient selection, and shared decision-making for patients at high risk of severe disease.
Target Audience
This educational activity is intended for primary care physicians (PCPs), infectious disease (ID) specialists, critical care physicians, hospitalists, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the treatment of COVID-19.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe unmet needs in the prevention and management of COVID-19.
- Assess emerging clinical trial evidence informing the use of current and investigational therapies for the prevention of COVID-19.
- Implement individualized strategies for patients at risk of COVID-19 tailored to disease severity and patient-specific factors.

Charles Vega, MD, FAAFP
Clinical Professor, Department of Family Medicine
UC Irvine School of Medicine
Santa Ana, CA
Disclosures: Advisor, Consultant, Fee for Service Recipient: Boehringer Ingelheim, Exact Sciences, GSK

Stefan Gravenstein, MD, MPH
Professor of Medicine
Director, Division of Geriatrics and Palliative Medicine
Brown University
Providence, RI
Disclosures: Advisor, Consultant, Fee For Service Recipient: AstraZeneca, Genentech, GSK, Moderna, Pfizer, Sanofi; Speakers Bureau: Moderna, Sanofi; Grant/Research Funding: Genentech, GSK, Moderna, Pfizer, Sanofi

Elie Saade, MD, MPH
Associate Professor of Medicine
Medical Director, UH Infection Control
Case Western Reserve University
Cleveland, Ohio
Disclosures: Grant/Research Funding: Johnson & Johnson, Pfizer, Shionogi
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity
was planned in accordance with the ACCME Standards for Integrity and
Independence to ensure balance, objectivity, independence, and scientific
rigor. Faculty were instructed to use generic names when possible and to base
recommendations on the best available evidence. Proprietary product names may
be referenced in clinical discussion for educational purposes only and do not
imply endorsement.
This activity may include discussion of
investigational, unapproved, or off‑label uses of
drugs or devices. Learners are advised to consult prescribing information for
products discussed. Content is provided for educational purposes only and is
not a substitute for the independent clinical judgment of a health care
professional. Learners are encouraged to critically evaluate the information
presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools
to support educational development. All content was reviewed and approved by
qualified faculty or planners. The accredited provider retains full
responsibility for accuracy, balance, and independence.
